If you have been diagnosed with prostate cancer, we can help


We can help you To learn more about prostate cancer through guest speakers, books, DVDs and newsletters;
To make better decisions about what treatment to have (you can talk to men who have had the different treatments that you may be considering);
To meet others who are going through the same thing as you (avoid feeling isolated and alone)

We are a peer support group ( a group of men and women who have been affected by prostate cancer) who provide information, education and support. We are affiliated with the Prostate Cancer Foundation of Australia.

Evidence shows that:
Peer support can reduce the psychological stress associated with prostate cancer diagnosis; and
Support groups can improve the quality of life and well being of people with prostate cancer and their carers.

If you need help before our next meeting, please phone one of the people listed on the Contact Page.

Peter MacCallum Centre has new research grants

Peter Mac researchers have received a major funding boost ($5.4m) for two new clinical trials of a game-changing radioactive molecule purpose made to kill prostate cancer cells. The Commonwealth Government and Movember Foundation this week announced a co-investment of $4 million to advance a new targeted therapy pioneered at the Peter MacCallum Cancer Centre called PSMA Theranostics.

The treatment, LuPSMA (Lutetium-177 PSMA-617), uses a radioactive molecule that binds only to prostate cancer cells with minimal impact on neighbouring healthy cells.

This funding will also allow this research alliance to study a new form of immunotherapy called CAR T-cell therapy for men with prostate cancer which does not respond to the Lutetium-177 treatment.

Peter Mac patient Barry Elderfield, who responded favourably to LuPSMA treatment in the original pilot study, said this new funding was a very exciting development. To see the extension of LuPSMA trials to include men with newly-diagnosed advanced metastatic prostate cancer and less advanced cancer is just thrilling.

Click this link to the Peter MacCallum Centre web site for full details.

Tuesday, 16th April 2019: Associate Professor Miranda Xhilaga: Director of Research Programs, Prostate Cancer Foundation of Australia will be speaking on
                 Current research which is exciting me

Miranda holds an MBBS from Tirana University and a PhD in molecular biology from Monash University, and has an interest in Knowledge Translation (KT), having trained as a KT specialist at the University of Toronto. As Director of Research Programs at thge Prostate Cancer Foundation of Australia she is responsible for the implementation and development of strategies that increase coordinated prostate cancer research activities nationwide, research evaluation and knowledge transfer.

Study exploring men’s experiences and needs regarding vocational rehabilitation, work and retirement after prostate cancer diagnosis.

This study is being led by Dr Vanette McLennan at the Menzies Health Institute Queensland, Griffith University.  It is intended to provide valuable information toward improving vocational support and services for men with prostate cancer.

It involves the completion of an online survey about the barriers and facilitators to employment and how these may have impacted on return to work or early retirement after prostate cancer. There are also some questions regarding mental and sexual health to help us understand their impact on return to work

You may be eligible for this study if you:

  • have been diagnosed with prostate cancer, and
  • were employed in any capacity (including self-employment) at the time of prostate cancer diagnosis.

Further information is available at https://griffithmhiq.co1.qualtrics.com/jfe/form/SV_9Y5Ns1Pg1U1QvHv

Clinical Trial of Estradiol Gel to Prevent Side Effects of ADT

Austin Health is conducting a Clinical Trial investigating whether estradiol gel applied to the skin can prevent side effects of Androgen Deprivation Therapy such as bone loss, muscle loss, hot flushes and fat gain.  Please contact Dr Nick Russell, Endocrinologist, Men’s Health Clinic, nicholas.russell@austin.org.au to know more.

New Trial Weight Loss Program

Edith Cowan University is seeking volunteers who are currently undergoing Androgen Deprivation Therapy (hormone blocking therapy) to take part in a Weight Loss Program for Prostate Cancer Patients.  The lead investigator is Ms Rebekah Wilson.

Summary of project

Androgen deprivation therapy (ADT) is a common treatment for prostate cancer. One of the many possible side effects of this treatment is weight gain. Lifestyle changes utilising exercise and diet have been demonstrated as safe and result in improved health, physical function, and quality of life for cancer patients. The purpose of this study is to assess the efficacy of an exercise and diet programme designed to induce weight loss.

The study timeline will include a 6-week waiting period, followed by a 3-month exercise and diet intervention, and a further 3-month home-based programme. The participant will be required to attend a series of testing days during this time including assessment of body composition (fat, muscle, and bone mass), resting metabolic rate, blood and inflammatory markers, physical function (muscular strength, aerobic fitness), dietary monitoring, and quality of life.

The 3-month exercise and diet intervention will involve completing 3 supervised exercise sessions a week for 12 weeks and attending 3 nutritional counselling sessions during this time. The exercise will include individually prescribed resistance and aerobic training accumulating 300 minutes/week (45 minutes/day). The nutrition component will also be individually prescribed and focus on decreasing portion sizes and advise on carbohydrate, fat, and protein consumption.

Ethics approval

Ethics approval has been granted by Edith Cowan University Human Research Ethics Committee.

Who is this study for?

You may be eligible for this study if you:

  • Be currently receiving androgen deprivation therapy (hormone blocking therapy) as part of your prostate cancer treatment plan;
  • Have no bone metastasis (tumours spread to bones)
  • Have no secondary cancer diagnosis
  • Have no medical conditions that may prevent you completing an exercise programme.
  • Comfortably walk 400 m.

You would need to meet all the above criteria to be involved in this study.

For more information, please contact:

Name: Rebekah Wilson, phone: (08) 6304 3444, email: r.wilson@ecu.edu.au